Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol
Lung-MAP (S1400) was created to establish an infrastructure for biomarker screening and rapid regulatory intent evaluation of targeted therapies. Eligible patients were aged 18 years or older, had stage IV or recurrent squamous non-small-cell lung cancer. Median overall survival was 5.9 months for the targeted therapy groups, 7.7 months for docetaxel groups.
